Phase 2 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who took part in the previous related trial and have signed a consent form agreeing to move into this follow-on stage.
- People who fully completed the previous related trial.
- Women who could become pregnant must have had a negative pregnancy test at the start of this stage of the trial.
- Women who could become pregnant, and men who could father a child with a partner who could become pregnant, must be willing to continue using highly effective birth control throughout the trial.
Who may not be able to join:
- People who had a serious side effect from the study drug ORKA-001 during the previous trial that caused them to permanently stop taking it, or where the trial doctor believes continuing the drug would not be safe for them.
- People who developed a specific form of psoriasis (guttate, erythrodermic, pustular, or medication-triggered psoriasis) during the previous trial, as diagnosed by the trial doctor.
- People who have a current or past significant health condition other than psoriasis, or a finding from a medical check, that the trial doctor believes could affect their safety or the reliability of the trial results.
- People whose most recent blood or laboratory test results from the previous trial showed a significant abnormality that the trial doctor believes would make continuing the study drug unsafe.
- People who are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 781-560-0299
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.